FDA Approves New Tablet to Reduce Stroke, Heart Attack Risk

The agency approves Zontivity to reduce the risk of heart attack, stroke and cardiovascular death in high risk patients

The FDA recently approved the drug Zontivity (vorapaxar) to reduce the risk of stroke, heart attack and cardiovascular death in high risk patients, the FDA reports. The tablets also reduce the need for procedures to restore blood flow to the heart. The medication is ideal for use in patients who have previously had a heart attack or blockages in the arteries to the legs.

A clinical trial with over 25,000 patients showed that when added to other anti-platelet agents such as aspirin, Zontivity reduced the rate of a combined endpoint of heart attack, stroke, cardiovascular death and urgent procedures to improve blood flow to the heart.

According to the FDA, Zontivity is “the first in a new class of drug, called a protease-activated receptor-1 (PAR-1) antagonist.” The tablets are designed to decrease the tendency of platelets to clump together and form a blood clot, which in turn decreases the risk of heart attack or stroke. The drug does increase the risk of bleeding, however, and should not be used in people who have had a stroke, transient ischemic attack or bleeding in the head because of the risk of bleeding.  

“In patients who have had a heart attack or who have peripheral arterial disease, this drug will lower the risk of heart attack, stroke, and cardiovascular death. In the study that supported the drug’s approval, Zontivity lowered this risk from 9.5 percent to 7.9 percent over a 3-year period – about 0.5 percent per year,” said Ellis Unger, M.D., director of the Office of Drug Evaluation I in the FDA’s Center for Drug Evaluation and Research, in the FDA’s press release.

Download Center

HTML - No Current Item Deck
  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • The Top 5 Safety and Technology Trends to Watch

    Get the latest on trends you can expect to hear more about in 2019, including continued growth of mobile safety applications, wearable technology, and smart PPE; autonomous vehicles; pending OSHA recordkeeping rulemaking; and increased adoption of international safety standard, ISO 45001.

  • Analyze Incident Data

    Collect relevant incident data, analyze trends, and generate accurate regulatory reports, including OSHA 300, 300A, and 301 logs, through IndustrySafe’s extensive incident reporting and investigation module.

  • Safety Training 101

    When it comes to safety training, no matter the industry, there are always questions regarding requirements and certifications. We’ve put together a guide on key safety training topics, requirements for certifications, and answers to common training questions.

  • Conduct EHS Inspections and Audits

    Record and manage your organization’s inspection data with IndustrySafe’s Inspections module. IndustrySafe’s pre-built forms and checklists may be used as is, or can be customized to better suit the needs of your organization.

  • Industry Safe
comments powered by Disqus

OH&S Digital Edition

  • OHS Magazine Digital Edition - January 2019

    January / February 2019

    Featuring:

    • PREVENTING ERRORS
      Production vs. Safety 
    • EMERGENCY SHOWERS & EYEWASH
      Meeting the Requirements for Emergency Equipment
    • CONSTRUCTION SAFETY
      The State of Contractor Safety
    • FOOT PROTECTION
      The Three Keys to Effective Chemical Management
    View This Issue